Daiichi Sankyo

Daiichi Sankyo to establish Japan’s first mRNA production facility

22-Feb-2023 By Jane Byrne

Daiichi Sankyo is kitting out a plant, based near Tokyo in Kitamoto, with equipment to enable the production of an mRNA vaccine against COVID-19, according to a Nikkei Asia report.

AZ bets billions on Daiichi’s ADC therapy

28-Jul-2020 By Ben Hargreaves

AZ agrees deal with Daiichi to co-develop a treatment in oncology, as part of its ADC strategy.

Daiichi pays $225m to access gene therapy production platform

06-Apr-2020 By Ben Hargreaves

Daiichi partners with Ultragenyx to utilize its HeLa producer cell line platform for commercial-scale gene therapy production.

AZ’s ADC receives priority review

17-Oct-2019 By Ben Hargreaves

US FDA provides AZ and Daiichi Sankyo’s ADC for the treatment of metastatic breast cancer priority review, with a decision set for Q2 2020.

Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC

03-Aug-2018 By Maggie Lynch

Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.

Daiichi Sankyo: looming Benicar patent loss and large molecule focus prompted plant closure

06-Apr-2016 By Gareth Macdonald

Closure of its Benicar intermediates plant was prompted by impending US patent loss and a decision to focus on large molecule drugs says Daiichi Sankyo.